Answers - Finance

There are these automatic portfolio management systems. They operate with the prec

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ision of a Swiss watchmaker.

How it works.

You start with a certain portfolio th

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

t is established according to a standard investment mix. This mix could be in line

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

with you personal preferences; let’s say that 80% of the portfolio is to be inves

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ed in stocks and 20% is to be kept liquid.

Than according to new savings you can

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

feed the automatic portfolio management system and the money is invested according

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

to the mix. Entering $ 1000,- will end up as $ 800,- converted to stock and 200 do

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

llar on your current (investment) account.

Now, the stock exchange is dynamic and

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

the day-to-day changes will vary. On a periodic basis however, your portfolio dist

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ribution is calculated and balanced against the standard mix you started with.

No

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

if stock prices rise, your portfolio will be out of balance. Reckon that you star

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ed with 8000 dollar in stocks and 2000 dollars cash. If the value of the stock in

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

portfolio climbed to lets say 9000, the new distribution of stock will be outside

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

he 80% level (nearly 82%).

So the automatic portfolio system, will sell the extra

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

percentage of stock in order to rebalance the portfolio. To keep it in line with

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

hat you want!

This is a very rational system. Just doing the right thing. Somethi

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ng that is very hard for people that – like most of us – have a unequal judgment a

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

out the stock market; if the market climbs we are prone to take more risk. But we

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

are just fooling ourselves.

Once you have questioned your risk-return profile, yo

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.answers.org.ua/article/104005/answers-The-Investment-Challenge-Selling-When-Stock-Prices-Are-Rising.html">The Investment Challenge: Selling When Stock Prices Are Rising</a>

BB link (for phorums):
[url=http://www.answers.org.ua/article/104005/answers-The-Investment-Challenge-Selling-When-Stock-Prices-Are-Rising.html]The Investment Challenge: Selling When Stock Prices Are Rising[/url]

There is no doubt that interest in corporate governance has substantially increased in recent years. Not only have separate states adopted their own corporate codes but also changes in corporate governance are directed at a global level.

Going once! Going twice! Sold! Sound familiar? It’s the sound of a traditional live auction but, thanks to the technology of today, you can buy and sell 24 hours a day, 7 days a week. Here's how to do it properly!

A breakdown of some of the considerations that web masters and small work at home businesses need to consider before using common search engine optimization (SEO) writing techniques.

Tags

Links

Answers - The Investment Challenge: Selling When Stock Prices Are Rising

Related Articles: